Search Results - "Karsh, Lawrence Ivan"

Real-world clinical outcomes of patients with localized prostate cancer (LPC) treated with external beam radiation therapy (EBRT) by Karsh, Lawrence Ivan, Du, Shawn, He, Jinghua, Waters, Dexter, Muser, Erik, Shore, Neal D.

“…330 Background: Patients (pts) with localized prostate cancer (LPC) or locally advanced prostate cancer (PC) have several treatment options, including external…”
Get full text

Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS) by Maughan, Benjamin L., Mundle, Suneel, Nematian-Samani, Mehregan, Wang, Xiayi, Du, Shawn, Liu, Yanfang, Karsh, Lawrence Ivan

“…65 Background: Over the last decade,androgen receptor signaling inhibitors (ARSIs; apalutamide [APA], enzalutamide [ENZ], abiraterone acetate + prednisone…”
Get full text

VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer by Lerner, Seth P., Karsh, Lawrence Ivan, O'Donnell, Michael A., Shore, Neal D., Lotan, Yair, Tsuji, Shingo, Giacalone, Matthew

“…Abstract only 488 Background: VAX014 is a novel tumor targeted oncolytic agent for intravesical administration. It is comprised of recombinant bacterial…”
Get full text

Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry by Shevrin, Daniel H., Symanowski, James Thomas, Shore, Neal D., Lin, Daniel W., Russell, David, Kral, Pavol, Song, Yi, El-Chaar, Nader N., Karsh, Lawrence Ivan

“…e17085 Background: Significant lack of treatment (Tx) intensification is seen in clinical practice for pts with mHSPC until progression to mCRPC. The TRUMPET…”
Get full text

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design by Agarwal, Neeraj, Azad, Arun, Shore, Neal D, Carles, Joan, Fay, Andre P, Dunshee, Curtis, Karsh, Lawrence Ivan, Paccagnella, Maria Luisa, Santo, Nicola Di, Elmeliegy, Mohamed, Lin, Xun, Czibere, Akos, Fizazi, Karim

“…PARP inhibitors in combination with androgen receptor-targeted therapy have demonstrated potential in the treatment of metastatic castration-resistant prostate…”
Get full text

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results by Aggarwal, Rahul Raj, Zhang, Jingsong, Zhu, Xinhua, Monk, Paul, Jones, Robert J., Linch, Mark David, Costin, Dan, De Bono, Johann S., Karsh, Lawrence Ivan, Petrylak, Daniel P., Borderies, Pascal, Deshpande, Rashmi Majali, Hafeez, Amir, O'Neill, Vincent J., Tagawa, Scott T.

“…176 Background: BXCL701 (talabostat), oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP8/9 & DPP4—triggers inflammasome to alert and…”
Get full text

Factors related to men’s experience with prostate cancer germline testing by Giri, Veda N., Gross, Laura, Hartman, Rebecca, Leader, Amy, Whang, Young E., Couvillon, Anna, Cheng, Heather H., Paller, Channing Judith, Loeb, Stacy, Karsh, Lawrence Ivan, Friedman, Sue J., Beer, Tomasz M., Sokolova, Alexandra, Keith, Scott W.

“…128 Background: Indications for prostate cancer (PCA) germline testing (GT) have greatly expanded, with genetics delivery being implemented in a variety of…”
Get full text

BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC) by Aggarwal, Rahul Raj, Costin, Dan, Zhang, Jingsong, Karsh, Lawrence Ivan, Healey, Diane I., Linch, Mark David, Adurthi, Sreenivas, Petrylak, Daniel Peter, O'Neill, Vince, Monk, Paul

“…Abstract only 124 Background: BXCL701 (talabostat), oral small molecule inhibitor of dipeptidyl peptidases (DPP), primarily DPP8 and DPP9, triggers…”
Get full text

Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies by Small, Eric Jay, Chi, Kim N., Chowdhury, Simon, Bevans, Katherine B., Bhaumik, Amitabha, Saad, Fred, Chung, Byung, Karsh, Lawrence Ivan, Oudard, Stephane, De Porre, Peter, Brookman-May, Sabine D., McCarthy, Sharon Anne, Mundle, Suneel, Uemura, Hirotsugu, Smith, Matthew Raymond, Agarwal, Neeraj

“…Abstract only 73 Background: In phase 3 placebo (PBO)-controlled studies, addition of APA to androgen deprivation therapy (ADT) improved overall survival,…”
Get full text

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results by Tagawa, Scott T., Zhang, Jingsong, Monk, Paul, Zhu, Xinhua, Jones, Robert, Linch, Mark David, Costin, Dan, De Bono, Johann S., Karsh, Lawrence Ivan, Petrylak, Daniel P., Borderies, Pascal, Deshpande, Rashmi Majali, O'Neill, Vincent, Aggarwal, Rahul Raj

“…Abstract only 126 Background: BXCL701 (talabostat), oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 & DPP 4—triggers…”
Get full text

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results by Zhang, Jingsong, Aggarwal, Rahul Raj, Tagawa, Scott T., Linch, Mark David, Petrylak, Daniel P., Costin, Dan, De Bono, Johann S., Jones, Robert, Karsh, Lawrence Ivan, Zhu, Xinhua, Borderies, Pascal, Deshpande, Rashmi Majali, O'Neill, Vincent, Monk, Paul

“…Abstract only 125 Background: BXCL701 (talabostat), oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 & DPP 4—triggers…”
Get full text

Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Azad, Arun, Fizazi, Karim, Matsubara, Nobuaki, Fong, Peter C.C., Carles, Joan, Shore, Neal D., De Giorgi, Ugo, Jones, Robert J., Karsh, Lawrence Ivan, Joung, Jae Young, Fay, Andre P., Liu, Glenn, Yip, Steven M., Zschaebitz, Stefanie, Hopkins, Julia F., Di Santo, Nicola, Lin, Xun, Mata, Marielena, Laird, Douglas, Agarwal, Neeraj

“…5056 Background: In TALAPRO-2 (NCT03395197), pts unselected for tumor genetic alterations in DNA damage repair pathways, directly or indirectly involved with…”
Get full text

A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Abida, Wassim, Bradley, Thomas Paul, Rezazadeh, Arash, Karsh, Lawrence Ivan, Ross, Ashley, Saltzstein, Daniel, Argon, Evren Kocabas, Hamlett, Anthony, Tang, Jeanie, Adib, Deyaa

“…Abstract only TPS255 Background: The histone methyltransferase EZH2 is overexpressed in many cancers. In prostate cancer (PC), EZH2 inhibition may reverse…”
Get full text

TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC) by Agarwal, Neeraj, Azad, Arun, Shore, Neal D., Carles, Joan, Fay, Andre P., Dunshee, Curtis, Karsh, Lawrence Ivan, Paccagnella, Maria Luisa, Di Santo, Nicola, Elmeliegy, Mohamed, Lin, Xun, Niyazov, Alexander, Czibere, Akos, Fizazi, Karim

“…Abstract only TPS5089 Background: TALA blocks poly(ADP-ribose) polymerase (PARP) activity and traps PARP on single-strand DNA breaks, preventing DNA damage…”
Get full text

Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) by Agarwal, Neeraj, Shore, Neal D., Dunshee, Curtis, Karsh, Lawrence Ivan, Sullivan, Beth, Di Santo, Nicola, Elmeliegy, Mohamed, Lin, Xun, Czibere, Akos Gabor, Fizazi, Karim

“…Abstract only 5076 Background: TALA is a dual-mechanism PARP inhibitor that inhibits PARP catalytic activity and traps PARP on DNA. ENZA is a novel hormonal…”
Get full text

Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience by Berry, William R., Pieczonka, Christopher Michael, Vogelzang, Nicholas J., Karsh, Lawrence Ivan, Bailen, James L., Van Velzen, Krista, Kandadi, Harini, Sheikh, Nadeem Anwar, Dakhil, Shaker R.

“…Abstract only e16504 Background: Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant…”
Get full text

TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) by Agarwal, Neeraj, Shore, Neal D., Dunshee, Curtis, Karsh, Lawrence Ivan, Sullivan, Beth, Di Santo, Nicola, Elmeliegy, Mohamed, Lin, Xun, Quek, Ruben G.W., Czibere, Akos Gabor, Fizazi, Karim

“…Abstract only TPS5092 Background: ENZA is approved to treat men with CRPC. TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP1/PARP2 and…”
Get full text

The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN by Chi, Kim N., Merseburger, Axel S., Ozguroglu, Mustafa, Chowdhury, Simon, Bjartell, Anders, Chung, Byung, Pereira de Santana Gomes, Andrea Juliana, Given, Robert, Juárez, Álvaro, Uemura, Hirotsugu, Ye, Dingwei, Karsh, Lawrence Ivan, Gartrell, Benjamin Adam, Brookman-May, Sabine D., Mundle, Suneel, McCarthy, Sharon Anne, Lefresne, Florence, Rooney, Oliver Brendan, Bhaumik, Amitabha, Agarwal, Neeraj

“…Abstract only 89 Background: Addition of androgen receptor signaling inhibitors to ADT + DOC has been shown to improve clinical outcomes in pts with mCSPC…”
Get full text

Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events by Karsh, Lawrence Ivan, Penson, David F., Concepcion, Raoul, Flanders, Scott, Brown, Bruce A., Yang, Hongbo, Ramaswamy, Krishnan, Schultz, Neil M.

“…Abstract only 228 Background: Androgen receptor inhibitors enzalutamide (ENZA) and bicalutamide (BIC) are used to treat metastatic castration-resistant…”
Get full text

TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) by Agarwal, Neeraj, Shore, Neal D., Dunshee, Curtis, Karsh, Lawrence Ivan, Sullivan, Beth, Di Santo, Nicola, Elmeliegy, Mohamed, Casey, Michelle, Quek, Ruben G.W., Czibere, Akos, Fizazi, Karim

“…Abstract only TPS337 Background: ENZA is approved to treat men with CRPC. TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP1/PARP2 and…”
Get full text